Inhibition studies of the protozoan α-carbonic anhydrase from Trypanosoma cruzi with phenols

Alessandro Bonardi\textsuperscript{a,b}, Seppo Parkkila\textsuperscript{b,c} and Claudiu T. Supuran\textsuperscript{a}  
\textsuperscript{a}Neurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence, Sesto Fiorentino (FI), Italy; \textsuperscript{b}Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; \textsuperscript{c}Fimlab Ltd, Tampere University Hospital, Tampere, Finland

ABSTRACT  
The α-class carbonic anhydrase (CA, EC 4.2.1.1) from the protozoan pathogen Trypanosoma cruzi, TcCA, was investigated earlier for its inhibition with anions, sulphonamides, thiols and hydroxamates, well-known classes of CA inhibitors (CAIs). Here we present the first inhibition study of this enzyme with phenols, which possess a diverse CA inhibition mechanism compared to the previously investigated compounds, which are all zinc binders. Indeed, phenols are known to anchor to the zinc coordinated water molecule within the enzyme active site. In a series of 22 diversely substituted phenols, the best inhibitors were simple phenol, pyrocatechol, salicylic acid, 3,5-difluorophenol, 3,4-dihydroxy-benzoic acid, 3,6- dihydroxy-benzoic acid, caffeic acid and its des-hydroxy analog, with $K_I$s of 1.8 – 7.3 μM. The least effective TcCA inhibitor was 3-chloro-4-amino-phenol (Kₐ of 47.9 μM). Although it is not yet clear whether TcCA can be considered as an anti-Chagas disease drug target, as no animal model for investigating the antiprotzoal effects is available so far, finding effective in vitro inhibitors may be a first relevant step towards new antiprotzoal agents.

1. Introduction

Protozoans are microscopic, nonfilamentous protists belonging to a multitude of phyla, with many genera and species described so far, many of which possess ecological and industrial relevance. However, they sometimes produce disease in vertebrates, which may range from mild to moderate, such as those induced by Toxoplasma gondii or Entamoeba histolytica, or may lead to more serious conditions, in the case of infections due to Cryptosporidium parvum, Giardia lamblia, Trichomonas vaginalis, Babesia spp., but also very serious and widespread ones, such as malaria, leishmaniasis, Chagas disease, and African sleeping disease\textsuperscript{1,2}. Although rare, there are also several fatal protozoal diseases, mostly provoked by amoebae belonging to Naegleria fowleri, Acanthamoeba spp. and Balamuthia mandrillaris genera/species\textsuperscript{1}. Few effective therapeutic approaches are available so far for treating most diseases provoked by protozoans\textsuperscript{1}. Albeit all 12 protozoans genera which produce human disease are well studied by now, there are few drugs useful for treating them. Furthermore, these drugs have been available for many decades, generally show high toxicity and low therapeutic indexes, and more concerning, extensive resistance to these treatment options has developed in the last period\textsuperscript{1,2}.  

Among the prozoan diseases which drew much attention in the last decade is Chagas's disease (CD), provoked by Trypanosoma cruzi, a pathogen thought to be endemic to South America, but which is nowadays also infecting people in Europe and North America\textsuperscript{3–7}. This parasite possesses an intricate life cycle, with many growth stages, not all of which are sensitive to the two clinically used drugs, nifurtimox and benznidazole, both of them belonging to the nitro-azole, old class of antiprotzoal drugs\textsuperscript{1,2,7}. Thus, there is a stringent need of new drug targets for fighting CD, and although many of them have been proposed so far\textsuperscript{8}, no relevant progress has been achieved for the moment\textsuperscript{7}.  

An α-class carbonic anhydrase (CA, EC 4.2.1.1) has been identified, cloned and characterised in the genome of T. cruzi few years ago by our groups\textsuperscript{3}. This enzyme, denominated TcCA, was shown to possess high catalytic activity for the conversion of CO₂ into bicarbonate and protons\textsuperscript{5}, was also shown to be inhibited, sometimes quite efficiently, by the main classes of CA inhibitors (CAIs), such as the anions, sulphonamides, thiols and hydroxamates\textsuperscript{3–6}. In some cases interesting antiprotzoal effects were also observed ex vivo in cell cultures with some of them, e.g. hydroxamates and sulphonamides formulated as nanoemulsions\textsuperscript{6,7}. It is not yet definitively clear whether TcCA can indeed be considered as an anti-CD drug target, since no animal model for investigating the antiprotzoal effects is available so far\textsuperscript{1,2}. However, the interesting in vitro and ex vivo data available with many classes of CAIs (not all of which possess the optimal pharmacological properties, such as for example a facile membrane penetration\textsuperscript{8}) prompts us to continue the investigation of new classes of inhibitors targeting this pathogenic enzyme. Here we report the first inhibition study of TcCA with a series of phenols, well-known inhibitors of CA\textsuperscript{8–11}.

2. Materials and methods

2.1. Enzymology and CA activity and inhibition measurements

Production and purification of recombinant TcCA have been previously described by our groups\textsuperscript{3}. An Applied Photophysics
A stopped-flow instrument was used to assay the CA-catalysed CO$_2$ hydration activity\(^1\). Phenol red (0.2 mM) was used as a pH indicator, working at the absorbance maximum of 557 nm, with 10 mM HEPES (pH 7.4) as a buffer, and in the presence of 10 mM NaClO$_4$ to maintain constant ionic strength, in order to follow the initial rates of the CA-catalysed CO$_2$ hydration reaction for a period of 10$^{-10}$ to 100 s. The CO$_2$ concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. TcCA concentration in the assay system was 10.6 nM. For each inhibitor, at least six traces of the initial 5$^{-10}$% of the reaction were used to determine the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of inhibitors (10$^{-20}$ mM) were prepared in distilled-deionized water, and dilutions up to 10 nM were done thereafter with the assay buffer. Inhibitor and enzyme solutions were preincubated together for 15 min prior to the assay, in order to allow for the formation of the E-I complex. The inhibition constants were obtained by non-linear least-squares methods using Prism 3 and the Cheng-Prusoff equation, as reported previously\(^3\,^4\), and represent the mean from at least three different determinations.

| Table 1. Inhibition data of human CA isoforms I and II and protozoan enzyme TcCA by a stopped-flow CO$_2$ hydrase assay method [12] using the sulphonamide acetazolamide (AAZ) as standard drug |
|---|---|---|---|---|---|---|---|---|
| Name | Structure | hCA I | hCA II | TcCA | $K_i$ (μM)$^a$ |
|---|---|---|---|---|---|
| 1 | | 10.2 | 5.5 | 3.4 | |
| 2 | | >100 | 5.5 | 2.1 | |
| 3 | | >100 | 9.4 | 32.7 | |
| 4 | | 10.7 | 0.1 | 18.5 | |
| 5 | | >100 | >100 | 13.2 | |
| 6 | | 4.9 | 4.7 | 41.7 | |
| 7 | | >100 | >100 | 25.3 | |
| 8 | | 10.0 | 6.2 | 19.8 | |
| 9 | | >100 | 0.1 | 15.1 | |
| 10 | | 9.9 | 7.1 | 4.5 | |
| 11 | | 9.8 | 10.6 | 28.4 | |
| 12 | | 68.9 | 95.3 | 17.8 | |
| 13 | | 6.3 | 4.9 | 13.6 | |
| 14 | | 57.8 | 57.5 | 47.9 | |
| 15 | | >100 | >100 | 21.1 | |
| 16 | | | | | 38.8 | 33.9 | 7.3 |
| 17 | | | | | >100 | >100 | 26.9 |
| 18 | | | | | 1.1 | 0.5 | 2.4 |
| 19 | | | | | 5.7 | 5.2 | 15.9 |
| 20 | | | | | 4.2 | 4.1 | 7.1 |
| 21 | | | | | 1.1 | 1.3 | 4.8 |
| 22 | | | | | 2.4 | 1.6 | 1.8 |
| AAZ | – | | | | 0.25 | 0.012 | 0.06 |

$^a$Mean from three different assays, by a Stopped-Flow technique (errors were in the range of ± 5–10% of the reported values).
2.2. Chemistry

Compounds 1–22, buffers, acetazolamide AAZ and other reagents were of > 99% purity and were commercially available from Sigma-Aldrich (Milan, Italy).

3. Results and discussion

CAs possess several classes of inhibitors which interact with the enzyme in a rather intricate and sometimes unexpected way13–16. Indeed, the classical inhibitors, such as the inorganic/organic anions, as well as the sulphonamides and their isosteres (sulfamides and sulfamates) coordinate to the catalytic metal ion, which is crucial for catalysis, and substitute the coordinated nucleophilic water molecule/hydroxide ion13,14. However, many classes of CAs identified more recently, such as the phenols, polyamines, sulfocoumarins, alcohols, etc., interact with the enzyme in diverse modes, inhibiting it by anchoring to the metal-ion coordinated water molecule15,16, obstructing the entrance to the active site17,18, or even binding outside the active site19. In particular, phenols, polyphenols, alcohols and more recently β-mercaptopethanol16,17 were shown by X-ray crystallography to anchor with their OH moiety by means of hydrogen bond(s) to the zinc coordinated water molecule (eventually making other strong interactions with amino acid residues in the neighbourhood of the catalytic core) in α-, β- and γ-CAs, making this inhibition mechanism a quite general one13–14. Initially, Lindskog’s group20 reported phenol to act as a weak CAI, whereas Christiansson’s group then resolved the X-ray crystal structure of this compound bound to the human(II) isoform hCA II21. Since then, many synthetic and natural phenols/polyphenols were investigated for their interaction with many CAs of diverse origin, leading to the discovery of interesting leads10,11,20–24.

Considering the wealth of literature data on inhibition of various CAs from mammals and pathogenic organisms with phenols, and the lack of such studies for the inhibition of TcCA, here we report the inhibition of this enzyme with a library of 22 phenols (Table 1) investigated earlier for their interaction with human, bacterial and plasmodial CAs10–24. The following structure activity relationship (SAR) can be evidenced from the inhibition data presented in Table 1, in which the hCA I and II inhibition data are also provided for comparison reasons:

i. All phenols investigated here of types 1–22 inhibited TcCA with Ks in the micromolar range, more precisely of 1.8–47.9 μM. It should be noted that the investigated compounds incorporate one, two or three phenolic OH moieties, and generally one two or three other simple substituents, of the amino, hydroxyl, halogeno, carboxy, cyano, acetamido or hydroxymethyl type. Few of them (21 and 22) possess the carboxyethenyl moiety which is slightly bulkier compared to the moieties present in the other scaffolds of type 1–20 (Table 1).

ii. The most effective TcCA inhibitors were 1, 2, 10, 16, 18 and 20–22, with Ks in the range of 1.8–7.3 μM. They include the simple phenol 1, pyrocatechol 2, salicylic acid 10, 3,5-difluorophenol 16, 3,4-dihydroxy-benzoic acid 18, 3,6- dihydroxybenzoic acid 20 as well as caffeic acid 22 and its des-hydroxy analog 21. The best inhibitor was just caffeic acid 22 (K of 1.8 μM) as well as pyrocatechol 2 (K of 2.1 μM). It should be noted that caffeic acid in fact incorporates in its molecule the pyrocatechol fragment, also present in 18 (the next most effective inhibitor in this series). However, this fragment not always induced the most effective inhibitory power, as in compound 5, it only led to a moderate inhibitor (K of 13.2 μM).

iii. Slightly weaker TcCA inhibitory effects compared to the compounds discussed above were observed for the following phenols: 4, 5, 8, 9, 12, 13, and 19, which possessed Ks in the range of 13.2–19.8 μM. The structure activity relationship (SAR) is again not easy, since apart 19, which is a 2,6-dihydroxy-substituted phenol, the other derivatives generally have a 4-substituent, of the OH, CN, acetamido, hydroxymethyl or Cl type. Thus, the structural diversity is rather high in order to draw straightforward SAR conclusions.

iv. The least effective TcCA inhibitors were 3, 6, 7, 11, 14, 15, and 17, which showed Ks in the range of 21.1–47.9 μM. As mentioned above, also these derivatives possess a heterogeneous structure which makes SAR discussions not easy to interpret. However, it seems that the presence of amino groups in meta or para to the phenol functionality (as in 6 and 14) was associated with weaker TcCA inhibitory properties. In fact these two compounds are the least effective inhibitors (Ks of 41.7–47.9 μM). The presence of a chlorine in para (in addition to the amino in meta) however increased the inhibitory power, since compound 13 was a more effective TcCA inhibitor (K of 13.6 μM) compared to 14. These two compounds are position isomers, which demonstrates that even small structural changes may lead to dramatic differences in the inhibitory power.

v. TcCA has a very diverse inhibition profile with phenols compared to the human isofoms hCA I and II, for which these compounds showed very diverse Ks (Table 1). However, all phenols are much weaker CAs compared to the sulphonamide acetazolamide, which is a nanomolar inhibitor for all three enzymes.

4. Conclusions

Recently, several groups showed that the inhibitors of bacterial CAs may lead to effective compounds for fighting drug resistant bacteria24–26, although there was some relevant scepticism that these enzymes could be considered as antiinfective drug targets27. It took more than 10 years since the first proposal that bacterial CAs may be new drug targets for the development of antibiotics28 till the actual in vivo validation of some of them, many of which present in relevant and drug resistant bacterial pathogens, such as Enterococci, Neisseria spp., Helicobacter pylori, etc.25,26. This was only possible through a dedicated medicinal chemistry approach for developing new CAIs selective for the bacterial over the human enzymes, but also due to the development of animal models of such bacterial diseases in which many of these compounds were tested26. In the case of the protozoan CAs, although there are plenty of effective and rather selective in vitro inhibitors, there is a lack of animal models of most such infections, partly due to the complicated life cycles of these pathogens. This is particularly true in the case of CD: T. cruzi has two evolutive forms, with the first one being the circulating infective but not replicative form, known as trypomastigotes, and the second one being the replicative, intracellular form, known as amastigotes, which have also been shown to be infective1,2. Thus, as long as there will be impossible to test the efficacy of newly designed enzyme inhibitors, as those investigated here, on both evolutive forms of T. cruzi it is difficult to estimate the real contribution of protozoan CAs in the pathogenicity and infectiveness of these protozoa.
Disclosure statement

The authors have no relevant affiliations of financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. CT Supuran is Editor-in-Chief of the Journal of Enzyme Inhibition and Medicinal Chemistry. He was not involved in the assessment, peer review, or decision-making process of this paper. The authors have no relevant affiliations of financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Funding

CTS thank the Italian Ministry for University and Research (MIUR), project FISR2019_04819 BacCAD. The research program was also funded by the Academy of Finland (SP).

ORCID

Seppo Parkkila http://orcid.org/0000-0001-7323-8536
Claudiu T. Supuran http://orcid.org/0000-0003-4262-0323

References

1. Vermelho AB, Mori M, Donald WA, Supuran CT. Challenges and promises for obtaining new antiprotozoal drugs: what’s going wrong? In: Vermelho AB, Supuran CT, eds. Antiprotozoal drug development and delivery. Cham (Switzerland): Springer Nature; 2022:321–330.

2. (a) Nocentini A, Vermelho AB, Supuran CT. Targeting carbonic anhydrases from Trypanosoma cruzi and Leishmania spp. as a therapeutic strategy to obtain new antiprotozoal drugs. In: Vermelho AB, Supuran CT, eds. Antiprotozoal drug development and delivery. Cham (Switzerland): Springer Nature; 2022:83–112. (b) Vermelho AB, Cardoso V, Mansoldo FRP, et al. Chagas disease: drug development and parasite targets. In: Vermelho AB, Supuran CT, eds. Antiprotozoal drug development and delivery. Cham (Switzerland): Springer Nature; 2022:49–82.

3. Pan P, Vermelho AB, Capaci Rodrigues G, et al. Cloning, characterization, and sulfonamide and thiol inhibition studies of an χ-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease. J Med Chem 2013;56:1761–71.

4. (a) Pan P, Vermelho AB, Scozzafava A, et al. Anion inhibition studies of the χ-carbonic anhydrase from the protozoan pathogen Trypanosoma cruzi, the causative agent of Chagas disease. Bioorg Med Chem 2013;21:4472–6. (b) Rodrigues GC, Feijó DF, Bozza MT, et al. Design, synthesis, and evaluation of hydroxamic acid derivatives as promising agents for the management of Chagas disease. J Med Chem 2014;57:298–308.

5. (a) Supuran CT. Inhibition of carbonic anhydrase from Trypanosoma cruzi for the management of Chagas disease: an underexplored therapeutic opportunity. Future Med Chem 2016;8:311–24. (b) Capasso C, Supuran CT. Bacterial, fungal and protozoan carbonic anhydrases as drug targets. Expert Opin Ther Targets 2015;19:1689–704. (c) Vermelho AB, Capaci GR, Rodrigues IA, et al. Carbonic anhydrases from Trypanosoma and Leishmania as anti-protozoan drug targets. Bioorg Med Chem 2017;25:1543–55. (d) D’Ambrosio K, Supuran CT, De Simone G. Are carbonic anhydrases suitable targets to fight protozoan parasitic diseases? Curr Med Chem 2019;25:5266–78.

6. (a) Nocentini A, Cadoni R, Dumy P, et al. Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani chagasi are inhibited by benzoxaboroles. J Enzyme Inhib Med Chem 2018;33:286–9. (b) Vermelho AB, da Silva Cardoso V, Ricci Junior E, et al. Nanoemulsions of sulfonamide carbonic anhydrase inhibitors strongly inhibit the growth of Trypanosoma cruzi. J Enzyme Inhib Med Chem 2018;33:139–46. (c) Nocentini A, Osman SM, Almeida IA, et al. Appraisal of anti-protozoan activity of nitroaromatic benzene-sulfonamides inhibiting carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani. J Enzyme Inhib Med Chem 2019;34:1164–71. (d) Bonardi A, Vermelho AB, da Silva Cardoso V, et al. N-nitrosulfonamides as carbonic anhydrase inhibitors: a promising chemotype for targeting Chagas disease and Leishmaniasis. ACS Med Chem Lett 2019;10:413–8. (e) Llanos MA, Sbaraglini ML, Villalba ML, et al. A structure-based approach towards the identification of novel antichagasic compounds: Trypanosoma cruzi carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2020;35:21–30.

7. (a) Vermelho AB, Rodrigues GC, Supuran CT. Why hasn’t there been more progress in new Chagas disease drug discovery? Expert Opin Drug Discov 2020;15:145–58. (b) Mansoldeo FRP, Carta F, Angeli A, et al. Chagas disease: perspectives on the past and present and challenges in drug discovery. Molecules 2020;25:5483.

8. Simonsson I, Jonsson BH, Lindskog S. Phenol, a competitive inhibitor of CO2 hydration catalyzed by carbonic anhydrase. Biochim Biophys Res Commun 1982;108:1406–12.

9. Nair SK, Ludwig PA, Christianson DW. Two-site binding of phenol in the active site of human carbonic anhydrase II: structural implications for substrate association. J Am Chem Soc 1994;116:3659–60.

10. (a) Innocenti A, Vullo D, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV). Bioorg Med Chem Lett 2008;18:1583–7. (b) Innocenti A, Vullo D, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem 2008;16:7424–8. (c) Innocenti A, Hilvo M, Scozzafava A, et al. Carbonic anhydrase inhibitors: inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett 2008;18:3593–6. (d) Davis RA, Innocenti A, Poulsen SA, Supuran CT. Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isoforms VA and VB over the cytosolic isoforms I and II from a natural product-based phenolic library. Bioorg Med Chem 2010;18:184–8. (e) Davis RA, Hofmann A, Osman A, et al. Natural product-based phenols as novel probes for mycobacterial and fungal carbonic anhydrases. J Med Chem 2011;54:1682–92.

11. (a) Innocenti A, Gökçin I, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I–XV. Bioorg Med Chem Lett 2010;20:5050–3. (b) Sarikaya SB, Gökçin I, Supuran CT. Carbonic anhydrase inhibitors: inhibition of human
erythrocyte isozymes I and II with a series of phenolic acids. Chem Biol Drug Des 2010;75:515–20. (c) Innocenti A, Beyza Öztürk Sarikaya S, Gülçin İ, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of mammalian isozymes I–XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem 2010;18:2159–64.

12. Khalilah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971; 246:2561–73.

13. (a) Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012; 27: 759–72. (b) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60.

14. (a) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81. (b) Nocentini A, Angeli A, Carta F, et al. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem 2021;36:561–80. (c) Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med Res Rev 2020;40:2485–565.

15. (a) Supuran CT. Novel carbonic anhydrase inhibitors. Future Med Chem 2021;13:1935–7. (b) Supuran CT. Emerging role of carbonic anhydrase inhibitors. Clin Sci (Lond) 2021;135: 1233–49. (c) Zimmerman SA, Ferry JG, Supuran CT. Inhibition of the archaeal beta-class (Cab) and gamma-class (Cam) carbonic anhydrases. Curr Top Med Chem 2007;7:901–8. (d) Mori M, Supuran CT. Acipimox inhibits human carbonic anhydrases. J Enzyme Inhib Med Chem 2022;37:672–9.

16. (a) Andring J, Combs J, McKenna R. Aspirin: a suicide inhibitor of carbonic anhydrase II. Biomolecules 2020;10:527. (b) D’Ambrosio K, Carradori S, Cesa S, et al. Catechols: a new class of carbonic anhydrase inhibitors. Chem Commun (Camb) 2020;56:13033. (c) Simone DG, Bua S, Supuran CT, Alterio V. Benzylic alcohol inhibits carbonic anhydrases by anchoring to the zinc coordinated water molecule. Biochem Biophys Res Commun 2021;548:217–21. (d) Fiore A, De Luca V, Langella E, et al. Biochemical, structural, and computational studies of a γ-carbonic anhydrase from the pathogenic bacterium Burkholderia pseudomallei. Comput Struct Biotechnol J 2022;20:4185–94.

17. (a) Maresca A, Temperini C, Yu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057–62. (b) Maresca A, Temperini C, Pochet L, et al. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem 2010;53:333–44. (c) Maresca A, Supuran CT. Coumarins incorporating hydroxy- and chloro-moieties selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II. Bioorg Med Chem Lett 2010;20:4511–4. (d) Temperini C, Innocenti A, Scozzafava A, et al. The coumarin-binding site in carbonic anhydrase accommodates structurally diverse inhibitors: the antiepileptic lacasamide as an example and lead molecule for novel classes of carbonic anhydrase inhibitors. J Med Chem 2010; 53:850–4.

18. (a) Petreni A, Osman SM, Alasmry FA, et al. Binding site comparison for coumarin inhibitors and amine/amino acid activators of human carbonic anhydrases. Eur J Med Chem 2021;226:113875. (b) Fuentes-Aguilar A, Merino-Montiel P, Montiel-Smith S, et al. 2-Aminobenzoxazole-appended coumarins as potent and selective inhibitors of tumour-associated carbonic anhydrases. J Enzyme Inhib Med Chem 2022; 37:168–77. (c) Giovanniuzzi S, Hewitt CS, Nocentini A, et al. Coumarins effectively inhibit bacterial α-carbonic anhydrases. J Enzyme Inhib Med Chem 2022;37:333–8. (d) Onyé Imaz M, Koca M, Bonardi A, et al. Isocoumarins: a new class of selective carbonic anhydrase IX and XII inhibitors. J Enzyme Inhib Med Chem 2022;37:743–8.

19. D’Ambrosio K, Carradori S, Monti SM, et al. Out of the active site binding pocket for carbonic anhydrase inhibitors. Chem Commun (Camb) 2015;51:302–5.

20. (a) Ekinci D, Kurbanoğlu NL, Salami E, et al. Carbonic anhydrase inhibitors: inhibition of human and bovine isoenzymes by benzenesulphonamides, cyclitols and phenolic compounds. J Enzyme Inhib Med Chem 2012;27:845–8. (b) Öztürk Sarıkaya SB, Topal F, Sentürk M, et al. In vitro inhibition of α-carbonic anhydrase isoforms by some phenolic compounds. Bioorg Med Chem Lett 2011;21:4259–62. (c) Sentürk M, Gülçin İ, Beydemir S, et al. In vitro inhibition of human carbonic anhydrase I and II isozymes with natural phenolic compounds. Chem Biol Drug Des 2011;77:494–9.

21. (a) Carta F, Vullo D, Maresca A, et al. Mono-/dihydroxybenzoic acid esters and phenol pyridinium derivatives as inhibitors of the mammalian carbonic anhydrase isoforms I, II, VII, IX, XII and XIV. Bioorg Med Chem 2013;21:1564–9. (b) Maresca A, Akuyuz G, Osman SM, et al. Inhibition of mammalian carbonic anhydrase isoforms I–XIV with a series of phenolic acid esters. Bioorg Med Chem 2015; 23:7181–8. (c) Burmaoğlu S, Dilek E, Yılmaz AO, Supuran CT. Synthesis of two phloroglucinol derivatives with cinnamyl moieties as inhibitors of the carbonic anhydrase isozymes I and II: an in vitro study. J Enzyme Inhib Med Chem 2016;31:208–12.

22. (a) Ekinci D, Karagöz L, Ekinci D, et al. Carbonic anhydrase inhibitors: in vitro inhibition of α isoforms (hCA I, hCA II, bCA III, hCA IV) by flavonoids. J Enzyme Inhib Med Chem 2013;28:283–8. (b) Scozzafava A, Passaponti M, Supuran CT, Gülçin İ. Carbonic anhydrase inhibitors: guaiacol and catechol derivatives effectively inhibit certain human carbonic anhydrase isoenzymes (hCA I, II, IX and XIII). J Enzyme Inhib Med Chem 2015;30:586–91. (c) Karioti A, Ceruso M, Carta F, et al. New natural product carbonic anhydrase inhibitors incorporating phenol moieties. Bioorg Med Chem 2015;23: 7219–25. (d) Karioti A, Carta F, Supuran CT. Phenols and polyphenols as carbonic anhydrase inhibitors. Molecules 2016; 21:1649.

23. (a) Entezari Heravi Y, Bua S, Nocentini A, et al. Inhibition of Malassezia globosa carbonic anhydrase with phenols. Bioorg Med Chem 2017;25:2577–82. (b) Nocentini A, Bua S, Del Prete S, et al. Natural polyphenols selectively inhibit β-carbonic anhydrase from the danduff-producing fungus Malassezia globosa: activity and modeling studies. ChemMedChem 2018; 13:816–23. (c) Paloukopoulou C, Govari S, Soulioti A, et al. Phenols from Origanum dictamnus L. and Thymus vulgaris L. and their activity against Malassezia globosa carbonic anhydrase. Nat Prod Res 2022;36:1558–64.

24. (a) Nocentini A, Osman SM, Del Prete S, et al. Extending the γ-class carbonic anhydrases inhibition profiles with phenolic compounds. Bioorg Chem 2019;93:103336. (b) Alissa SA, Alghuliikah HA, ALOthman ZA, et al. Inhibition survey with phenolic compounds against the δ- and η-class carbonic anhydrases from the marine diatom Thalassiosira weissflogii
and protozoan *Plasmodium falciparum*. J Enzyme Inhib Med Chem 2020;35:377–82. (c) Grande R, Carradori S, Puca V, et al. Selective inhibition of *Helicobacter pylori* carbonic anhydrases by carvacrol and thymol could impair biofilm production and the release of outer membrane vesicles. Int J Mol Sci 2021;22:11583. (d) Giovannuzzi S, Hewitt CS, Nocentini A, et al. Inhibition studies of bacterial α-carbonic anhydrases with phenols. J Enzyme Inhib Med Chem 2022;37:666–71.

25. (a) Supuran CT, Capasso C. Biomedical applications of prokaryotic carbonic anhydrases. Expert Opin Ther Pat 2018;28:745–54. (b) Supuran CT, Capasso C. Antibacterial carbonic anhydrase inhibitors: an update on the recent literature. Expert Opin Ther Pat 2020;30:963–82. (c) Hewitt CS, Abutaleb NS, Elhassanny AEM, et al. Structure-activity relationship studies of acetazolamide-based carbonic anhydrase inhibitors with activity against *Neisseria gonorrhoeae*. ACS Infect Dis 2021;7:1969–84. (d) Nocentini A, Hewitt CS, Mastrolorenzo MD, et al. Anion inhibition studies of the α-carbonic anhydrases from *Neisseria gonorrhoeae*. J Enzyme Inhib Med Chem 2021;36:1061–6. (e) An W, Holly KJ, Nocentini A, et al. Structure-activity relationship studies for inhibitors for vancomycin-resistant *Enterococcus* and human carbonic anhydrases. J Enzyme Inhib Med Chem 2022;37:1838–44.

26. (a) Abutaleb NS, Elhassanny AEM, Seleem MN. *In vivo* efficacy of acetazolamide in a mouse model of *Neisseria gonorrhoeae* infection. Microb Pathog 2022;164:105454. (b) Flaherty DP, Seleem MN, Supuran CT. Bacterial carbonic anhydrases: underexploited antibacterial therapeutic targets. Future Med Chem 2021;13:1619–22. (c) Abutaleb NS, Elkashif A, Flaherty DP, Seleem MN. *In vivo* antibacterial activity of acetazolamide. Antimicrob Agents Chemother 2021;65:e01715–20.

27. (a) Fan SH, Matsuo M, Huang L, et al. The MpsAB bicarbonate transporter is superior to carbonic anhydrase in biofilm-forming bacteria with limited CO₂ diffusion. Microbiol Spectr 2021;9:e0030521. (b) Fan SH, Liberini E, Götz F. *Staphylococcus aureus* genomes harbor only MpsAB-like bicarbonate transporter but not carbonic anhydrase as dissolved inorganic carbon supply system. Microbiol Spectr 2021;9:e0097021.

28. Supuran CT. Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? Front Pharmacol 2011;2:34.